ATRC-101,Pembrolizumab
Atreca,merck
['solid tumor']
$bcel [15s. delayed]: issued press release on june 05, 08:00:00: atreca presents data from ongoing phase 1b study of atrc-101 in patients with select advanced solid tumors during oral abstract session at the asco 2023 annual meeting 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time